Preincisional and intraperitoneal ropivacaine plus normal saline infusion for postoperative pain relief after laparoscopic cholecystectomy: a randomized double-blind controlled trial

Abstract

Background: A clinical trial was designed to assess the use of preincisional and intraperitoneal ropivacaine, combined or not with normal saline, to reduce pain after laparoscopic cholecystectomy (LC).

Methods: For this trial, 120 patients were randomly assigned to six groups. For all the patients, preincisional local infiltration of ropivacaine around the trocar wounds was performed. Group A had infusion of ropivacaine at the beginning of the LC. Group B had infusion of ropivacaine at the beginning of the LC plus normal saline infusion at the end. Group C had normal saline infusion and ropivacaine at the end of the LC. Group D had infusion of ropivacaine at the beginning of the LC plus normal saline infusion at the end and a subhepatic closed drain. Group E had ropivacaine at the end of the LC. Group F (control group) had neither ropivacaine nor normal saline infusion. Shoulder tip and abdominal pain were registered at 2, 4, 6, 12, 24, 48, and 72 h postoperatively using a visual analog score (VAS).

Results: Significantly lower pain scores were observed in group B than in group A at 2, 4, 6, 12, and 24 h or in groups C, D, E, and F at 2, 4, 6, 12, 24, and 48 h. Group A also had significantly lower pain scores than groups C, D, E, and F at 2, 4, 6, 12, 24, and 48 h. Requests for analgesics also were significantly less in group B than in group A at 2, 4, 6, 12, and 24 h or in groups C, D, and E at 2, 4, 6, 12, 24, and 48 h. Demand for additional analgesia was less in group B than in groups A, C, D, E, and F at 2, 4, 6, 12, and 24 h and in group A than in groups C, D, E, and F at 2, 4, 6, and 12 h.

Conclusion: Preincisional local infiltration plus intraperitoneal infusion of ropivacaine at the beginning of LC combined with normal saline infusion at the end of the procedure is a safe and valid method for reducing pain after LC.